ClinConnect ClinConnect Logo
Search / Trial NCT04674449

iCorMicA - Stratified Medicine in Angina

Launched by NHS GREATER GLASGOW AND CLYDE · Dec 17, 2020

Trial Information

Current as of June 05, 2025

Recruiting

Keywords

Angina Microvascular Angina Ischaemia With No Obstructive Coronary Artery Disease (Inoca) Stratified Medicine Clinical Trial Outcomes Research Prognosis Health Economics

ClinConnect Summary

The iCorMicA study is looking at how different treatment plans can help people with angina, a type of chest pain, especially those who have symptoms but do not have blocked arteries. The goal is to see if a personalized treatment approach, guided by a special diagnostic procedure during a heart test called coronary angiography, can improve symptoms, overall well-being, and heart health in these patients. This trial is currently recruiting participants aged 18 and older who are scheduled for this heart test and have angina symptoms.

To join the study, participants must not have a history of major heart surgery or serious blockages in their coronary arteries. Those who take part can expect to receive either the personalized treatment or a placebo (a "dummy" treatment) without knowing which one they are getting, as the trial is designed to be fair and unbiased. This means everyone will have an equal chance of receiving the actual treatment or the placebo. The study aims to provide important insights into how to better manage angina symptoms for many people.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age ≥18 years.
  • 2. A clinical plan for invasive coronary angiography.
  • 3. Symptoms of angina (typical or atypical) according to the Rose- and/or Seattle Angina questionnaires.
  • 4. Able to comply with study procedures.
  • 5. Able to provide informed consent.
  • Exclusion Criteria:
  • 1. A non-coronary primary indication for invasive angiography (e.g. valve disease, heart failure).
  • 2. History of coronary artery bypass surgery.
  • 3. Presence of obstructive disease evident in a main coronary artery (diameter \>2.5 mm), i.e. a coronary stenosis \>50% and/or a fractional flow reserve (FFR) ≤0.80\*.
  • 4. Logistical reason\*. \*These patients will enter a follow-up registry.

About Nhs Greater Glasgow And Clyde

NHS Greater Glasgow and Clyde (NHS GG&C) is one of the largest health organizations in the UK, dedicated to delivering high-quality healthcare services to a diverse population. As a clinical trial sponsor, NHS GG&C plays a pivotal role in advancing medical research and improving patient outcomes through innovative clinical studies. The organization is committed to upholding rigorous ethical standards and regulatory compliance, ensuring that all trials are conducted with the utmost care for participant safety and scientific integrity. With a focus on collaboration, NHS GG&C partners with academic institutions, healthcare professionals, and industry stakeholders to foster an environment conducive to groundbreaking research and the development of new therapies.

Locations

Glasgow, , United Kingdom

Clydebank, Scotland, United Kingdom

Patients applied

1 patients applied

Trial Officials

Colin Berry, MBChB, PhD

Study Chair

University of Glasgow

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials